Skip to main content

Publisher: Wiley-Blackwell

Volume 1, Number 3, July 2000

Favourites:
ADD

New French guidelines for antiretroviral treatment
pp. 133-136(4)
Authors: Delfraissy, J-F; of, behalf; of French researchers, a consensus panel composed; advocates, community

Favourites:
ADD
Favourites:
ADD

Management of HIV and pregnancy in England's North Thames Region 1999: a survey of practice in 21 hospitals
pp. 143-147(5)
Authors: Brook, Mg; Taylor, Gp; Dale, A; Lyall, Egh; Tomlinson, D

Favourites:
ADD

How generalizable are the results of large randomized controlled trials of antiretroviral therapy?
pp. 149-154(6)
Authors: Moore, Daj; Goodall, Rl; Ives, Nj; Hooker, M; Gazzard, Bg; Easterbrook, Pj

Favourites:
ADD

Disseminated infection due to Encephalitozoon cuniculi in a patient with AIDS: case report and review
pp. 155-161(7)
Authors: Fournier, S; Liguory, O; Sarfati, C; David-Ouaknine, F; Derouin, F; Decazes, Jm; Molina, Jm

Favourites:
ADD

A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users
pp. 162-163(2)
Authors: Staszewski, S; Haberl, A; Carlebach, A; Rottmann, C; Miller, V; Gute, P

Favourites:
ADD

A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient
pp. 164-165(2)
Authors: Rickerts, V; Bickel, M; Tews, J; Jacobi, V; Staszewski, S

Favourites:
ADD

O1 Compartmentalization of resistance mutations in HIV-1 between the lung and peripheral blood
pp. 166-166(1)
Authors: White, Nc; Israel-Biet, D; Coker, R; Mitchell, D; Clarke, Jr; Weber, Jn

Favourites:
ADD

O4 A novel point mutation assay for the detection of resistance to non-nucleoside reverse transcriptase inhibitors
pp. 167-167(1)
Authors: Frater, Aj; Braganza, R; Clarke, Jr; Weber, Jn; McClure, Mo

Favourites:
ADD

O5 Genotypic drug-resistance testing in early HIV infection
pp. 167-167(1)
Authors: Dean, Gl; Cane, P; Ratcliffe, D; Workman, J; Pillay, D; Williams, Di; Churchill, Dr; Fisher, M

Favourites:
ADD

O6 Genotypic resistance mutations and virological response to combination therapy in a clinical cohort
pp. 167-167(1)
Authors: Quigg, M; Harris, D; Precious, H; Clutterbuck, D; Nicoll, S; Burns, S; McMillan, A; Leen, C; Brown, Aj Leigh

Favourites:
ADD

O7 Structural solution of the HIV-1 packaging signal and use of RNA transcripts containing the signal as potential antiviral molecules
pp. 167-168(2)
Authors: Lever, Aml; Dorman, N; Chadwick, D; Hassard, S; Zeffman, A; Varani, G

Favourites:
ADD

09 One-year UK experience of nelfinavir in paediatric HIV-1
pp. 168-168(1)
Authors: Mitchla, Z.; Sharland, M.; Delmas, N.; Gibb, D.; Tudor-Williams, G.; Ball, C.; Dumont, G.; Klein, N.

Favourites:
ADD

O8 HIV post-exposure prophylaxis (PEP): a retrospective review
pp. 168-168(1)
Authors: Benn, P; Mercey, D; Williams, Ig

Favourites:
ADD

010 Quadruple HAART in primary infection: results from QUEST
pp. 168-169(2)
Authors: Lampe, F; Phillips, An; Kinloch, S; Johnson, M; Goh, L; Hawkins, D; Gazzard, B; Fisher, M; Freedman, A; Group, Study

Favourites:
ADD

012 AIDS-related lymphoma in the era of HAART
pp. 169-169(1)
Authors: Matthews, G; Bower, M; Mandalia, S; Powles, T; Nelson, M; Gazzard, B

Favourites:
ADD

011 The viral response to HAART over the first 16 weeks of therapy according to the pre-HAART and the 4–8-week viral load
pp. 169-169(1)
Authors: Lepri, A Cozzi; Miller, V; Phillips, An; Rabenau, H; Sabin, C; Staszewski, S

Favourites:
ADD

013 Normalization of intestinal permeability following antiretroviral therapy in HIV+ patients with diarrhoea
pp. 169-170(2)
Authors: Miao, Ym; Bjarnason, I.; Crane, R; Hayes, P; Gazzard, B

Favourites:
ADD

014 Does TB treatment alter virological and immunological response to HAART?
pp. 170-170(1)
Authors: Dean, Gl; Edwards, Sg; Navaratne, L; Matthews, G; Fox, Ef; Wood, Cg; Fisher, M; Churchill, Dr; Taylor, Gp; de Ruiter, A; Taylor, C; Pozniak, A

Favourites:
ADD

016 Type III hyperlipidaemia, related to PI treatment, is not caused by homozygosity for apoE2
pp. 170-170(1)
Authors: Jaleel, H; Shahmanesh, M; DeSilva, Y; Ross, Jdc; Caslake, M; Cramb, R

Favourites:
ADD

015 Rapid onset lipodystrophy syndrome (LD) in three patients with prior severe nucleoside toxicity
pp. 170-170(1)
Authors: de Burgh Thomas, A; Creighton, S; Edwards, Sg; Taylor, C

Favourites:
ADD

O19 CD4+ T–cell responses in early HIV infection
pp. 171-171(1)
Authors: Gloster, Se; Harrop, R; Newton, Pj; Cornforth, Dm; Balfe, P; Williams, Ig; Borrow, P

Favourites:
ADD

017 A prospective study of lipid metabolism in HIV-1-seropositive patients treated with HAART
pp. 171-171(1)
Authors: Morlese, J; Ware, L; Kruger, M; Pozniak, A; Jackson, A; Wooton, S; Gazzard, B

Favourites:
ADD

O18 A dichotomy in CD4 T-cell responses specific to HIV antigens
pp. 171-171(1)
Authors: Gotch, Fm; Imami, N; Gill, J; Westby, M; Wilson, Jdk

Favourites:
ADD

021 Assessment of thymic activity by positron emission tomography in HIV patients on HAART
pp. 172-172(1)
Authors: Worrell, S; Hardy, G; Hayes, P; Aspinal, R; Barnett, C; Dutton, J; Gotch, Fm; Gazzard, B

Favourites:
ADD

020 Antibody responses to HIV Gag and Env following highly active antiretroviral therapy (HAART)
pp. 172-172(1)
Authors: Deayton, J; Cope, Av; Sabin, C; Johnson, M; Griffiths, Pd; Emery, Vc

Favourites:
ADD

022 A heterosexual outbreak in Doncaster involving subtype B of HIV-1: molecular epidemiology as a supplement to contact tracing
pp. 172-172(1)
Authors: Hayman, A; Moss, T; Arnold, C; Naylor-Adamson, l; Hawkswell, J; Allen, K; Radford, J; Nguyen-Van-Tam, J; Balfe, P

Favourites:
ADD

024 Mortality in the HAART era
pp. 173-173(1)
Authors: Sullivan, Ak; Mazhude, C; Nelson, M; Fisher, M; Chard, S; Gazzard, B

Favourites:
ADD

023 Undiagnosed symptomatic acute HIV infections: a 12-month retrospective analysis of cases in South London
pp. 173-173(1)
Authors: Melzer, M; Brown, M; O'Shea, S; Mullen, J; Parry, J; Chrystie, I; Banatvala, J

Favourites:
ADD

P1 Assessing the role of treatment adherence in a clinical setting
pp. 173-173(1)
Authors: Jones, T; Pillay, D; Sabin, C; Back, D; Wilkins, E; Lloyd, J; Verbiest, W

Favourites:
ADD

P2 DAART –- a 1-year review
pp. 173-174(2)
Authors: Clarke, S; Harrington, P; Forkin, C; Curran, S; Keenan, E; Mulcahy, F

Favourites:
ADD
Favourites:
ADD

P3 The effect of nevirapine on the pharmacokinetics of methadone
pp. 174-174(1)
Authors: Clarke, S; Mulcahy, F; Barry, M; Tjia, J; Gibbons, S; Back, D

Favourites:
ADD

P4 Patients' perception of antiretroviral therapy
pp. 174-174(1)
Authors: Teltscher, Cm; Morgan, Rg; Bennie, M

Favourites:
ADD

P8 The effect of demographic and clinical factors on the natural history of viral load in HIV infection
pp. 175-175(1)
Authors: Sabin, C; Lepri, A Cozzi; Lee, C; Rezza, G; Johnson, M; Mocroft, A; Loveday, C; Phillips, An

Favourites:
ADD

P6 Demographics of 100 people testing HIV positive in the Royal Free Hospital in the preand post-HAART era
pp. 175-175(1)
Authors: Madge, S; Breen, R; Evans, A; Lepri, A Cozzi; Mocroft, A; Johnson, M

Favourites:
ADD
Favourites:
ADD

P9 Extended follow-up of ARV-naive patients treated with nevirapine
pp. 175-176(2)
Authors: Sabin, C; Churchill, Dr; Fisher, M; Pozniak, A; Hay, P; Easterbrook, P; Williams, Ig

Favourites:
ADD
Favourites:
ADD

P11 Access to HIV medical services by HIV-positive black Africans in London
pp. 176-176(1)
Authors: Erwin, J; Gray, K; Saul, J; Peters, B

Favourites:
ADD

P10 The relationships between ethnicity, gender, risk factor and viral load (VL) in HIV-1 antiretroviral naive patients
pp. 176-176(1)
Authors: Saul, J; Kulasegaram, R; Sabin, C; Erwin, J; Peters, B

Favourites:
ADD

P14 A preliminary cost analysis of management options for individuals with prior history of CMV disease
pp. 177-177(1)
Authors: Miners, A; Edmunds, Wj; Sabin, C; Mandalia, S; Youle, M; Pillay, D; Beck, Ej; of, behalf; Collaboration, the Npms-Hhc

Favourites:
ADD

P13 Assessing health-related quality-of-life in individuals with HIV/AIDS in the era of HAART
pp. 177-177(1)
Authors: Miners, A; Sabin, C; Youle, M; Mocroft, A; Dykhoff, A; Drinkwater, A; Johnson, M; Consortium, The Hiv Health Economics

Favourites:
ADD

P15 Survival of patients with AIDS 1983–99
pp. 177-177(1)
Authors: Chambers, E; Brettle, R; Wilson, A

Favourites:
ADD

P16 Dual nucleoside therapy in the era of HAART
pp. 177-178(2)
Authors: Mazhude, C; Randerson, S; Moriaty, S; Churchill, Dr; Fisher, M

Favourites:
ADD
Favourites:
ADD

P17 Response of individuals with high viral load to non-nucleoside reverse transcriptase inhibitors
pp. 178-178(1)
Authors: Nelson, M; Shaw, A; Baker, R; Bower, M; Fisher, M; Gazzard, B

Favourites:
ADD

P19 Response to second-line protease-inhibitor (PI) regimens: results from the EuroSIDA study
pp. 178-179(2)
Authors: Mocroft, A; Phillips, An; Miller, V; Gatell, J; van Lunzen, J; Lazzarin, A; on, Jd Lundgren; of, behalf; Group, the EuroSida Study

Favourites:
ADD

P21 Prevalence of antiretroviral resistance mutations in treatment-naive HIV-1-infected patients in South London
pp. 179-179(1)
Authors: Geretti, Am; Smith, M; Donati, M; Easterbrook, P; Zuckerman, M

Favourites:
ADD

P20 Triple protease inhibitor combinations in patients with multidrug resistant HIV infection
pp. 179-179(1)
Authors: Dragovic, B; Moyle, G; Youle, M; Smith, Na

Favourites:
ADD

P22 AZT genotypic resistance in patients not exposed to AZT
pp. 179-179(1)
Authors: Pozniak, A; Gilleece, Y; Nelson, M; Hertogs, K; Gazzard, B

Favourites:
ADD

P23 Resistance testing by population sequencing is not reproducible for mixed populations
pp. 180-180(1)
Authors: Frater, Aj; Chaput, Cc; Weber, Jn; McClure, Mo

Favourites:
ADD

P25 The relationship between ARV drug levels, drug resistance, adherence and treatment failure in a routine clinical setting
pp. 180-180(1)
Authors: Lloyd, J; Sabin, C; Pillay, D; Jones, T; Hoggard, P; Wilkins, E; Verbiest, W; Hertogs, K

Favourites:
ADD

P24 HIV resistance testing on archived samples aids current therapeutic decisions
pp. 180-180(1)
Authors: Dean, Gl; Fisher, M; Loveday, C

Favourites:
ADD

P26 The feasibility of therapeutic drug monitoring (TDM) for HIV protease inhibitors (PIs)
pp. 180-181(2)
Authors: Lloyd, J; Maher, B; Khoo, S; Gibbons, S; Back, D

Favourites:
ADD

P28 Cessation of secondary prophylaxis in patients with cryptococcosis
pp. 181-181(1)
Authors: Nwokolo, N; Theobald, N; Fisher, M; Nelson, M

Favourites:
ADD

P27 Long-term persistence of A098G RT mutation after cessation of non-nucleoside (NNRTI) therapy: a marker of NNRTI exposure
pp. 181-181(1)
Authors: Pozniak, A; Nwokolo, N; Nelson, M; Hertogs, K; Gazzard, B

Favourites:
ADD

P29 Successful treatment of relapsed visceral leishmaniasis in advanced HIV disease with oral miltefosine
pp. 181-182(2)
Authors: Churchill, Dr; Curry, Km; Fisher, M; Clein, Gp; Bryceson, Adm; Lockwood, Dnj

Favourites:
ADD

P32 Sexually acquired acute hepatitis C in homosexual men with HIV infection
pp. 182-182(1)
Authors: Smith, Am; Williams, Ig; Gilson, Rjc

Favourites:
ADD

P31 Changes in CD4 count and viral load during chemotherapy for AIDS-related lymphomas
pp. 182-182(1)
Authors: Powles, T; Fife, K; Nelson, M; Gazzard, B; Bower, M

Favourites:
ADD

P33 Antiretroviral therapy in the HIV/HCV co-infected patient
pp. 183-183(1)
Authors: Tall, R; Brettle, R; Wilson, A; Andrews, J; Williams, H; Leen, C; Cepeda, H

Favourites:
ADD

P35 Is there an association between choice of thymidine analogue and lipid abnormalities in HIV-1-infected patients?
pp. 183-183(1)
Authors: Matthews, G; Moyle, G; Mandalia, S; Bower, M; Nelson, M; Gazzard, B

Favourites:
ADD

P34 Failure of sequential nucleoside analogue monotherapy for the treatment of HBV in HIV/HBV co-infected patients
pp. 183-183(1)
Authors: Matthews, G; Ratcliffe, D; Cane, P; Pillay, D; Gazzard, B; Nelson, M

Favourites:
ADD

P36 Mechanisms of hyperlipidaemia in HIV patients on multitherapy including protease inhibitors
pp. 183-184(2)
Authors: Nair, Dr; Lister, Rk; Youle, M; Rustin, M; Mikhailidis, Dp; Winder, Af

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

P42 Discordant CD4 response on HAART
pp. 185-185(1)
Authors: Sullivan, Ak; Vlahakis, E; Mandalia, S; Nelson, M; Gazzard, B

Favourites:
ADD

P41 The reactivation of hepatitis B infection in an antiretroviral-naive patient treated with interleukin-2
pp. 185-185(1)
Authors: O'Moore, Ej; Doggett, Ta; McElborough, D; Fisher, M

Favourites:
ADD

P43 Immune responses in patients changing from PI to NNRTI-based HAART
pp. 186-186(1)
Authors: Sullivan, Ak; Nelson, M; Moyle, G; Mandalia, S; Gotch, Fm; Gazzard, B; Imami, N

Favourites:
ADD

P45 Analysis of lung and blood CD8 T lymphocytes in patients with HIV infection
pp. 186-186(1)
Authors: Barry, Sm; Tilling, R; Johnson, M; Janossy, G

Favourites:
ADD

P46 Lymphocyte migration to the gut in HIV infection and HAART
pp. 186-187(2)
Authors: Miao, Ym; Hayes, P; Gotch, Fm; Gazzard, B

Favourites:
ADD

P47 Recovery of functional immunity in HIV-infected patients on combination antiretroviral therapy
pp. 187-187(1)
Authors: Froebel, Ks; Howie, Fj; Howard, Wa; Leen, C; McMillan, A; Clutterbuck, D; Brown, Aj Leigh

Favourites:
ADD

P48 How reliable are data on HIV seroconversion illness? Is HIV test interval an adequate substitute?
pp. 187-187(1)
Authors: Gillett, J; on, K Porter; of, behalf; of Hiv, the Uk Register; Committee, Seroconverters Steering

Favourites:
ADD

P49 The natural course of viral load in a large database with known date of HIV seroconversion
pp. 187-188(2)
Authors: Lepri, A Cozzi; Sabin, C; Mocroft, A; Lee, C; Johnson, M; Loveday, C; Pezzotti, P; Rezza, G; Phillips, An

Favourites:
ADD

P50 Gender differences in response to HAART
pp. 188-188(1)
Authors: Moore, Al; Mocroft, A; Madge, S; Devereux, H; Wilson, D; Phillips, An; Johnson, M

Favourites:
ADD

P52 The continuing utility of autopsies in HIV/AIDS
pp. 188-188(1)
Author: Lucas, Sb

Favourites:
ADD

P51 Cervical screening in HIV-positive women: a cohort study
pp. 188-188(1)
Authors: Moore, Al; Mocroft, A; Reid, W; Madge, S; Johnson, M

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more